NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
51 hedge funds and large institutions have $9.56M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 50 → 51 (+1)
26% less capital invested
Capital invested by funds: $12.8M → $9.56M (-$3.28M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
60% less call options, than puts
Call options by funds: $395K | Put options by funds: $984K
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
51
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
OM
52
Opaleye Management
Boston,
Massachusetts
| – | -$1.18M | -915 | Closed |
|
53
D.E. Shaw & Co
New York
| – | -$167K | -130 | Closed |
|
|
CS
54
Credit Suisse
Zurich,
Switzerland
| – | -$84K | -65 | Closed |
|
|
VKH
55
Virtu KCG Holdings
New York
| – | -$48K | -38 | Closed |
|
56
Millennium Management
New York
| – | -$33K | -25 | Closed |
|
|
AIM
57
Advantage Investment Management
Cedar Rapids,
Iowa
| – | -$6K | -5 | Closed |
|
58
Wells Fargo
San Francisco,
California
| – | -$1.26K | -1 | Closed |
|
NBSE Hedge Fund Activity: Q2 2016 in Review
51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2016, worth a combined $9.56M — down 26% from $12.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NBSE positions and 7 closed out — a net gain of 2 holders — while 7 added to existing stakes and 11 trimmed.
The largest buyer was United Capital Financial Advisors, opening a new position worth an estimated $271K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.18M sold.
- 51 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2016, up from 50 in Q1 2016.
- Funds reported $9.56M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2016, down 26% quarter-over-quarter.
- 9 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2016 and 7 closed out, a net change of +2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2016 was United Capital Financial Advisors, an estimated $271K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2016 was Opaleye Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q2 2016.